Blood is pumped through the heart in one direction. Heart valves in this one-way blood flow, opening and closing with each heartbeat. The pressure changes on either side of the valves cause them to open their flap-type “doors” (called cups or leaflets) at just the right time, then close compactly to avert a backflow of blood. Doctors treat valves with medicines if they are not severe; otherwise, they are treated with surgeries to repair or replace the valve.
Valve repair can primarily be done on congenital valve defects. The company has a good success record with treating mitral valve defects. In contrast, severe valve damage implies the valve must be replaced and most often entails the aortic or mitral valve. It is also helpful in treating any life-threatening valve disease. Some patients may need more than one valve repaired or can be replaced.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-heart-valve-repair-and-replacement-market
Data Bridge Market Research analyzes that the Global Heart Valve Repair and Replacement Market is expected to reach USD 11,585.65 million by 2031 from USD 4,970.53 million in 2023, growing at a healthy CAGR of 11.3% in the forecast period of 2024 to 2031.
Key Findings of the Study
Rise in Incidence of Valvular Heart Defects
If the heart valves are diseased, the heart cannot effectively pump blood throughout the body. It must work continuously to pump, either while the blood leaks back into the chamber or against a narrowed opening. This can lead to heart failure, sudden cardiac arrest (when the heart stops beating), and death. Heart valve disease can develop quickly or over a long period. The symptoms may not show up until the condition is quite advanced, including shortness of breath, chest pain, fatigue, dizziness or fainting, fever, rapid weight gain, and irregular heartbeat when valve disease develops more steadily. Valvular heart disease, caused by damage or disease in heart valves, can result from congenital infections or degenerative or rheumatic conditions. Symptoms include shortness of breath, chest pain, fatigue, dizziness, fever, rapid weight gain, and irregular heartbeat. This valvular disease makes the patient prone to various health disorders, which may lead to death. Thus, the rise in the incidence of valvular heart defects is driving the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product (Surgical Heart Valves Replacement, Surgical Heart Valves Repair, TAVI/TAVR Valves, Grafts, Patches, Medication, and Others), Procedure (Surgical Procedure and Non-Surgical Procedure), Indication (Valvular Stenosis, Valvular Insufficiency, Mitral Valve Prolapse and Others), End User (Hospital, Specialty Centers, Cardiac Catheterization Lab, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Regions Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
MVRx, Inc. (U.S.), MeKo Laser Material Processing (Germany) Comed B.V. (Netherlands), CardiaMed (Netherlands), Xeltis (Netherlands), Foldax, Inc. (U.S.), JenaValve Technology (U.S.), Inc., Colibri Heart Valve (U.S.), HLT, Inc. (U.S.), NeoChord, Inc. (U.S.), Meril Life Sciences Pvt. Ltd. (India), Micro Interventional Devices, Inc. (U.S.), Biotronik (Germany), Medtronic (U.S.), Abbott (U.S.), Neovasc Inc.(Canada), and Edwards Lifesciences Corporation (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
The global heart valve repair and replacement market is segmented into five notable segments which are based the product, procedure, indication, end user, and distribution channel.
- On the basis of product, the market is segmented into surgical heart valves replacement, surgical heart valves repair, TAVI / TAVR valves, grafts, patches, medication, and others
In 2024, the surgical heart valves replacement segment is expected to dominate the market
In 2024, the surgical heart valves replacement segment is expected to dominate the market with 48.70% market share due to the increasing incidence of heart valve defect.
- On the basis of procedure, the market is segmented into surgical procedure and non-surgical procedure
In 2024, the surgical procedure segment is expected to dominate the market
In 2024, the surgical procedure segment is expected to dominate the market with 97.75% market share due to the rising demand for minimally invasive surgery and healthcare expenditure.
- On the basis of indication, the market is segmented into valvular stenosis, valvular insufficiency, mitral valve prolapse, and others. In 2024, the valvular stenosis segment is expected to dominate the market with 51.28% market share
- On the basis of end user, the market is segmented into hospital, specialty centers, cardiac catheterization lab, ambulatory surgical centers, and others. In 2024, hospital segment is expected to dominate the market with 61.44% market share
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2024, the direct tender segment is expected to dominate the market with 84.51% market share
Major Players
Data Bridge Market Research analyzes Abbott (U.S.), Edwards Lifesciences Corporation (U.S.), Medtronic (U.S.), Biotronik (Germany), Meril Life Sciences Pvt. Ltd. (India) as the major market players of the market.
Market Development
- In December 2023, Meril Life Sciences Pvt. Ltd. is excited to participate in COSECSA 2023, a prestigious event bringing together expertise in Cardiology, Diagnostics, Endo Surgery, and Orthopaedics
- In November 2023, Medtronic plc received FDA approval for the Symplicity Spyral renal denervation (RDN) system, allowing immediate commencement of commercialization. The approval marks a significant step for Medtronic in providing an advanced treatment option for hypertension using the Symplicity blood pressure procedure, reinforcing the company's commitment to healthcare technology innovation
- In October 2023, Edwards Lifesciences Corporation reported one-year results from CLASP IID, a groundbreaking randomized controlled trial comparing two contemporary mitral Transcatheter Edge-to-Edge Repair (TEER) therapies, alongside one-year results from the CLASP IID registry. The findings, presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) symposium and published in JACC: Cardiovascular Interventions, confirm the clinical and quality-of-life benefits of Mitral Regurgitation (MR) reduction with the PASCAL system. This marks a significant advancement in treating Degenerative Mitral Regurgitation (DMR) in a diverse patient population
- In April 2021, Abbott announced that it had received a CE mark for TriClip Tran’s catheter tricuspid valve repair system in Europe to treat tricuspid regurgitation. This will help the company in diversifying its business
- In March 2019 (Partnership), Micro Interventional Devices, Inc. announced that it has entered into a strategic alliance with OSCOR, Inc. that will leverage its unique capabilities and strength to further develop innovative solutions for structural heart disease
Regional Analysis
Geographically, the countries covered in the global heart valve repair and replacement market are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the heart valve repair and replacement market during the forecast period of 2024 to 2031
North America is expected to dominate the global heart valve repair and replacement market due to the strong presence of market players in the region and its cost saving nature of products.
Asia-Pacific is estimated to be the fastest growing region in the global heart valve repair and replacement market in the forecast period of 2024 to 2031
Asia-Pacific is expected to grow during the forecast period because of increasing awareness about heart health, a rising aging population, and improved access to advanced medical technologies.
For more detailed information about the global heart valve repair and replacement market report, click here – https://www.databridgemarketresearch.com/reports/global-heart-valve-repair-and-replacement-market
